395 related articles for article (PubMed ID: 25023322)
1. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
2. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
[TBL] [Abstract][Full Text] [Related]
3. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
[TBL] [Abstract][Full Text] [Related]
4. Acetate- and Citrate-Specific Ion Effects on Unfolding and Temperature-Dependent Aggregation Rates of Anti-Streptavidin IgG1.
Barnett GV; Razinkov VI; Kerwin BA; Hillsley A; Roberts CJ
J Pharm Sci; 2016 Mar; 105(3):1066-73. PubMed ID: 26886346
[TBL] [Abstract][Full Text] [Related]
5. A high-throughput UPLC method for the characterization of chemical modifications in monoclonal antibody molecules.
Stackhouse N; Miller AK; Gadgil HS
J Pharm Sci; 2011 Dec; 100(12):5115-25. PubMed ID: 21789770
[TBL] [Abstract][Full Text] [Related]
6. High-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
SLAS Discov; 2017 Sep; 22(8):1044-1052. PubMed ID: 28570837
[TBL] [Abstract][Full Text] [Related]
7. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
[TBL] [Abstract][Full Text] [Related]
8. High throughput thermostability screening of monoclonal antibody formulations.
He F; Hogan S; Latypov RF; Narhi LO; Razinkov VI
J Pharm Sci; 2010 Apr; 99(4):1707-20. PubMed ID: 19780136
[TBL] [Abstract][Full Text] [Related]
9. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
[TBL] [Abstract][Full Text] [Related]
10. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
11. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
Li Y; Mach H; Blue JT
J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438
[TBL] [Abstract][Full Text] [Related]
12. Conformational implications of an inversed pH-dependent antibody aggregation.
Perico N; Purtell J; Dillon TM; Ricci MS
J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
[TBL] [Abstract][Full Text] [Related]
13. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.
Franey H; Brych SR; Kolvenbach CG; Rajan RS
Protein Sci; 2010 Sep; 19(9):1601-15. PubMed ID: 20556807
[TBL] [Abstract][Full Text] [Related]
14. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
15. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration.
Kim N; Remmele RL; Liu D; Razinkov VI; Fernandez EJ; Roberts CJ
Biophys Chem; 2013 Feb; 172():26-36. PubMed ID: 23334430
[TBL] [Abstract][Full Text] [Related]
16. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
[TBL] [Abstract][Full Text] [Related]
17. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
18. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
19. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.
Razinkov VI; Treuheit MJ; Becker GW
J Biomol Screen; 2015 Apr; 20(4):468-83. PubMed ID: 25576149
[TBL] [Abstract][Full Text] [Related]
20. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
Zidar M; Šušterič A; Ravnik M; Kuzman D
Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
